Quaker Partners: Funding, Team & Investors

Date	Company	Round	Lead Investor(s)	Co-Investor(s)
Mar 16, 2021	Rapid Micro Biosystems	$81.0M Other Equity	D1 Capital Partners	Adage Capital Management, Ally Bridge Group, Asahi Kasei Medical, Bain Capital Life Sciences, BlackRock, Caas Capital Management, Endeavour Vision, Longitude Capital, Sunley House Capital, T. Rowe Price Associates, Xeraya Capital
May 29, 2019	Intact Vascular	$25.0M Other Equity	Justin Klein	H.i.g. Biohealth Partners, NEW Enterprise Associates
May 29, 2019	Vesper Medical	$37.0M Other Equity	Justin Klein	NEW Enterprise Associates
May 11, 2018	Vesper Medical	$10.5M Series A	Justin Klein, Quaker Partners	—
May 2, 2018	Rapid Micro Biosystems	$60.0M Other Equity	Jeff Schwartz, Fares Zahir	Asahi Kasei Medical, Longitude Capital, TVM Capital
Apr 1, 2018	Intact Vascular	$20.0M Series C	—	Vensana Capital, H.i.g. Biohealth Partners, Justin Klein
Jan 1, 2017	Intact Vascular	$7.0M Series B	—	Vensana Capital, H.i.g. Biohealth Partners, Justin Klein
May 1, 2015	Intact Vascular	$39.0M Series B	Justin Klein	Vensana Capital, H.i.g. Biohealth Partners
Apr 1, 2015	Rapid Micro Biosystems	$25.0M Series C	—	Apollo Health Ventures, Shawn LU, Kleiner Perkins, Longitude Capital, Richard King Mellon Foundation, Fred Cohen, TVM Capital
May 1, 2014	Tarsa Therapeutics	$7.0M Series B	—	Foresite Capital, MVM Partners, Novo Holdings
Dec 23, 2013	Intact Vascular	$4.7M Other Equity	—	H.i.g. Biohealth Partners
Jun 1, 2013	Rapid Micro Biosystems	$33.0M Series B	David Hirsch, Mark Braganza	Apollo Health Ventures, Kleiner Perkins, TVM Capital
Dec 1, 2012	Regado Biosciences	$51.0M Series E	Rusnanomedinvest	Domain Associates, Aurora Funds, Baxter Ventures, Caxton Advantage
Mar 1, 2012	Tarsa Therapeutics	$28.0M Series B	Foresite Capital	MVM Partners, Novo Holdings
Dec 30, 2011	Celator Pharmaceuticals	$2.6M Other Equity	—	Domain Associates, GrowthWorks, The Leukemia & Lymphoma Society, Ventures West
Jun 27, 2011	NovaSom	$35.0M Series D	James A. Datin	TPG
May 1, 2011	Neuronetics	$30.0M Series E	Kevin Bitterman	Access Biotechnology, Atlas Venture, Borealis Ventures, Flagship Ventures, GE Ventures, InterWest, SR ONE, Vivo Capital, Wildcat Ventures, Timothy A. Springer, Interwest Partners, Investor Growth Capital, NEW Leaf Venture Partners, ONSET Ventures, Three Arch Partners
Aug 1, 2010	Celator Pharmaceuticals	$20.0M Series D	Alex Zisson	Domain Associates, BDC Capital, GrowthWorks, TL Ventures, Ventures West
Jun 18, 2010	Precision Therapeutics	$35.0M Other Equity	Jeff Crisan	Adams Capital Management, Birchmere Ventures, Longitude Capital, TVM Capital
May 5, 2010	TearScience	$44.5M Series C	—	DE Novo Ventures, General Catalyst, Investor Growth Capital, Spray Venture Partners
Dec 1, 2009	Regado Biosciences	$40.0M Series D	—	Domain Associates, Aurora Funds, Caxton Advantage
Aug 2, 2007	Celator Pharmaceuticals	$10.0M Other Equity	—	BDC Capital, Domain Associates, GrowthWorks, Hearthstone Investments, TL Ventures, Ventures West
Aug 1, 2007	Celator Pharmaceuticals	$10.0M Series C	—	Domain Associates, BDC Capital, GrowthWorks, Hearthstone Investments, TL Ventures, Ventures West
Feb 22, 2006	Precision Therapeutics	$20.0M Series B	Quaker Partners	Adams Capital Management, Birchmere Ventures, Draper Triangle Ventures, Techno Venture Management

Quaker Partners is an East Coast-focused healthcare investment firm, deploying capital into companies at various development stages. It uses a traditional venture capital model, providing equity investments to enterprises specializing in pharmaceuticals, biotechnology, healthcare services, and medical technologies, including devices, tools, and human diagnostics. The firm emphasizes diversified opportunities within the healthcare landscape.

Founded in 2002 as Quaker BioVentures Inc., the firm was established by P. Sherrill Neff, Brenda Gavin, and Ira Lubert. Leadership later evolved its identity to Quaker Partners Management LP, broadening investment beyond biotechnology. This strategic shift reflected market dynamics, prompting a balanced healthcare investment approach for early-stage life science complexities.

The firm partners with innovative healthcare companies seeking growth capital and market entry support. Quaker Partners supports high-impact ventures bringing novel solutions to the healthcare sector, focusing on products or services nearing or already on the market. Its long-term vision centers on fostering advancements across the healthcare ecosystem through judicious, diversified investment.

Quaker Partners

Subscribe, Save or Share

Investment Activity

Investments Made

Financial History

Leadership Team

Leadership Team

About

Leadership Team

Investment Activity

Investments Made